Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus

Acta Physiologica

Volumn 214, Issue 2, 2015, Pages 176-188

  Kishore, B K ^a,b   Carlson, N G ^a,b   Ecelbarger, C M ^c,d   Kohan, D E ^a,b   Muller C E ^e   Nelson, R D ^a   Peti Peterdi, J ^f   Zhang, Y ^a,b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Arginine vasopressin; Collecting duct; P2Y12 receptor; P2Y2 receptor; Prostaglandins; Water channels

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; CLOPIDOGREL; CYCLIC AMP; LITHIUM; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC RECEPTOR; AQUAPORIN;

ASSOCIATION; BIPOLAR DISORDER; CONCENTRATION (PARAMETERS); DRUG USE; HUMAN; IN VITRO STUDY; KALIURESIS; KIDNEY COLLECTING TUBULE; KNOCKOUT MOUSE; NATRIURESIS; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; POLYURIA; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES INSIPIDUS, NEPHROGENIC; METABOLISM; PHYSIOLOGY;

ANIMALS; AQUAPORINS; ARGININE VASOPRESSIN; DIABETES INSIPIDUS, NEPHROGENIC; HUMANS; LITHIUM; NATRIURESIS; RECEPTORS, PURINERGIC P2Y2;

EID: 84929179813     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12507     Document Type: Review

References (93)

1. Ares, G.R., Caceres, P.S. & Ortiz, P.A. 2011. Molecular regulation of NKCC2 in the thick ascending limb. Am J Physiol Renal Physiol 301, F1143-F1159.
2. Baldenssarini, R.J., Pompili, M. & Tondo, L. 2006. Suicide in bipolar disorder: risks and management. CNS Spectr 11, 465-471.
3. Ball, S.G. 2007. Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin. Ann Clin Biochem 44, 417-431.
4. Baqi, Y. & Müller, C.E. 2010. Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions. Nat Protoc 5, 945-953.
5. 12 receptors. J Med Chem 52, 3784-3793.
6. Bedford, J.J., Leader, J.P., Jing, R., Walker, L.J., Klein, J.D., Sands, J.M. & Walker, R.J. 2008. Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 294, F812-F820.
7. Boone, M. & Deen, P.M. 2008. Physiology and pathophysiology of the vasopressin-regulated renal water absorption. Pflugers Arch 456, 1005-1024.
8. Breyer, M.D., Harris, R.C. & Breyer, R.M. 2013. Eicosanoids and renal function. In: R. Alpern, M. Caplan & O. Moe (eds) Seldin and Giebisch's The Kidney, 5th edn, pp. 487-509. Academic Press/Elsevier, London.
9. Brunschweiger, A. & Müller, C.E. 2006. P2 receptors activated by uracil nucleotides - an update. Curr Med Chem 13, 289-312.
10. Burnstock, G. & Verkhrastsky, A. 2012. Mechanisms of ATP release and inactivation. In: Purinergic Signalling and the Nervous System, pp. 79-118. Springer-Verlag, Berlin & Heidelberg.
11. Cade, J.F. 1949. Lithium salts in the treatment of psychotic excitement. Med J Aust 2, 349-352.
12. Christensen, B.M., Marples, D., Kim, Y.H., Wang, W., Frokiær, J. & Nielsen, S. 2004. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 286, C952-C964.
13. Christensen, B.M., Kim, Y.H., Kwon, T.H. & Nielsen, S. 2006. Lithium-treatment induces a marked proliferation of primary principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 291, F39-F48.
14. Chuang, D.M. 2004. Neuroprotective and neurotropic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 16, 83-90.
15. Conaghan, P.G. 2012. A turbylent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 32, 1491-1502.
16. - transport. J Biol Chem 274, 26461-26468.
17. Ecelbarger, C.A., Maeda, Y., Gibson, C.C. & Knepper, M.A. 1994. Extracellular ATP increases intracellular calcium in rat terminal collecting duct via a nucleotide receptor. Am J Physiol 267, F998-F1006.
18. Edwards, R.M. 2002. Basolateral, but not apical, ATP inhibits vasopressin action in rat inner medullary collecting duct. Eur J Pharmacol 438, 179-181.
19. Fenton, R.A., Pedersen, C.N. & Moeller, H.B. 2013. New insights into regulated aquaporin-2 function. Curr Opin Nephrol Hypertens 22, 551-558.
20. Finley, P.R., Warner, D. & Peabody, C.A. 1995. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 29, 172-191.
21. Gitlin, M. 1994. Lithium and the kidney: an update review. Drug Saf 20, 231-243.
22. Grünfeld, J.P. & Rossier, B.C. 2009. Lithium nephrotoxicity revisited. Nat Rev Nephrol 5, 270-276.
23. Hansen, H.E., Hestbech, J., Sorensen, J.L., Norgaard, K., Heilskov, J. & Amdisen, A. 1979. Chronic interstitial nephropathy in patients on long-term lithium therapy. Q J Med 48, 577-591.
24. Hays, R.M. & Leaf, A. 1961. The problem of clinical vasopressin resistance: in vitro studies. Ann Intern Med 54, 700-709.
25. 2 receptor offers long-term (5 mo) protection against lithium-induced polyuria, natriuresis and kaliuresis. J Am Soc Nephrol 25, 660A.
26. Hillmann, P., Ko, G.Y., Spinrath, A., Raulf, A., von Kügelgen, I., Wolff, S.C., Nicholas, R.A., Kostenis, E., Höltje, H.D. & Müller, C.E. 2009. Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J Med Chem 52, 2762-2775.
27. Hirschowitz, J., Kolevzon, A. & Garakami, A. 2010. The pharmacological treatment of bipolar disorder: the question of modern advances. Harv Rev Psychiatry 18, 266-278.
28. 12 receptor. J Pharmacol Exp Ther 331, 648-655.
29. Hoge, C.W., Castro, C.A., Messer, S.C., McGurk, D., Cottling, D. & Koffman, R.L. 2004. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 351, 13-22.
30. 2 receptor (-/-) mice. J Biol Chem 274, 26454-26460.
31. Jia, Z., Wang, H. & Yang, R. 2009. Mice lacking mPGES-1 are resistant to lithium-induced polyuria. Am J Physiol Renal Physiol 297, F1689-F1696.
32. Juul, K.V., Bichet, D.G., Nielsen, S. & Nørgaard, J.P. 2014. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol 306, F931-F940.
33. Kalantzi, K.I., Tsoumani, M.E., Goudevenos, I.A. & Tselepis, A.D. 2012. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Rev Clin Pharmacol 5, 319-336.
34. 2 receptor antagonists. Drug Dev Res 59, 72-81.
35. Kemp, P.A., Sugar, R.A. & Jackson, A.D. 2004. Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. Am J Respir Cell Mol Biol 31, 446-455.
36. Kishore, B.K. & Ecelbarger, C.M. 2013. Lithium: a versatile tool for understanding renal physiology. Am J Physiol Renal Physiol 304, F1139-F1149.
37. Kishore, B.K., Chou, C.-L. & Knepper, M.A. 1995. Extracellular nucleotide receptor inhibits AVP-stimulated water permeability in inner medullary collecting duct. Am J Physiol 269, F863-F869.
38. 2 purinoceptor in rat renal medulla and lung. Am J Physiol Renal Physiol 278, F43-F51.
39. 2 receptor mRNA and protein expression is altered in inner medullas of hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol 288, F1164-F1172.
40. 2 receptors and water transport in the kidney. Purinergic Signal 5, 491-499.
41. Klein, J.D., Blount, M.A. & Sands, J.M. 2011. Urea transport in the kidney. Compr Physiol 1, 699-729.
42. Kohan, D.E. 2011. Endothelin and collecting duct sodium and water transport. Contrib Nephrol 172, 94-106.
43. Kortenoeven, M.L., Li, Y., Shaw, S., Gaeggeler, H.-P., Rossier, B.C., Wetzels, J.F. & Deen, P.M. 2009. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 76, 44-53.
44. Manji, H.H., Moore, G.J. & Chen, G. 1999. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46, 929-940.
45. Marples, D., Christensen, S., Christensen, E.I., Ottosen, P.D. & Nielsen, S. 1995. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney. J Clin Invest 95, 1838-1845.
46. + excretion and arterial blood pressures by purinergic signalling intrinsic to the distal nephron: consequences and mechanisms. Acta Physiol 213, 213-221.
47. th anniversary of John Cade's discovery of the anti-manic effect of lithium. Aust N Z J Psychiatry 33, 623-628.
48. Murray, M.D. & Brater, D.C. 1993. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 32, 435-465.
49. Nguyen, T.A., Diodati, J.G. & Pharand, C. 2005. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45, 1157-1164.
50. Nielsen, S., Chou, C.-L., Marples, D., Christensen, E.I., Kishore, B.K. & Knepper, M.A. 1995. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasms membrane. Proc Natl Acad Sci USA 92, 1013-1017.
51. Nivoli, A.M., Murru, A. & Vieta, E. 2010. Lithium: still a corner stone in the long-term treatment in bipolar disorder? Neuropsychobiology 62, 27-35.
52. Oksche, A. & Rosenthal, W. 1998. The molecular basis of nephrogenic diabetes insipidus. J Mol Med (Berl) 76, 326-337.
53. Olesen, E.T. & Fenton, R.A. 2013. Is there a role for PGE2 in urinary concentration? J Am Soc Nephrol 24, 169-178.
54. Phelan, K.M., Mosholder, A.D. & Lu, S. 2003. Lithium interaction with the cyclooxygenase-2 inhibitiors refecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry 64, 1328-1334.
55. Prætorius, H. & Leipziger, J. 2010. Intrarenal purinergic signaling in the control of renal tubular transport. Annu Rev Physiol 72, 377-393.
56. Presen, C., Fakhouri, F., Noel, L.H., Stengel, B., Even, C., Kreis, H., Mignon, F. & Grünfeld, J.P. 2003. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int 64, 585-592.
57. Quiroz, J.A., Machado-Viera, R. & Zarate, C.A. Jr 2010. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62, 50-60.
58. Radin, M.J., Yu, M.J., Stoedkilde, L., Miller, R.L., Hoffert, J.D., Frokiær, J., Pisitkun, T. & Knepper, M.A. 2012. Aquaporin-2 regulation in health and disease. Vet Clin Pathol 41, 455-470.
59. Rao, R., Zhang, M.Z., Zhao, M., Cai, H., Harris, R.C., Breyer, M.D. & Hao, C.M. 2005. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 288, F642-F649.
60. Rieg, T. & Vallon, V. 2009. ATP and adenosine in the local regulation of water transport and homeostasis by the kidney. Am J Physiol Regul Integr Comp Physiol 296, R419-R427.
61. 2 receptors have salt-resistant hypertension and facilitated renal Na+ and water reabsorption. FASEB J 21, 3717-3726.
62. Rowe, M.K. & Chuang, D.M. 2004. Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 18, 1-18.
63. Sands, J.M. & Bichet, D.G. 2006. Nephrogenic diabetes insipidus. Ann Intern Med 144, 186-194.
64. Sands, J.M. & Layton, H.E. 2009. The physiology of urinary concentration: an update. Semin Nephrol 29, 178-195.
65. Sauer, R., El-Tayeb, A., Kaulich, M. & Müller, C.E. 2009. Synthesis of uracil nucleotide analogs with a modified, acyclic ribose moiety as P2Y(2) receptor antagonists. Bioorg Med Chem 17, 5071-5079.
66. 12-like receptor group. Purinergic Signal 3, 255-268.
67. Schwiebert, E.M. 2001. ATP release mechanisms, ATP receptors and purinergic signalling along the nephron. Clin Exp Pharmacol Physiol 28, 340-350.
68. Schwiebert, E.M. & Kishore, B.K. 2001. Extracellular nucleotides signaling along the renal epithelium. Am J Physiol Renal Physiol 280, F945-F963.
69. Sharma, R.K., Das, S.B., Lakshmikuttyamma, A., Selvakumar, P. & Srivastav, A. 2006. Regulation of calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1): review. Int J Mol Med 18, 95-105.
70. Shirley, D.G., Bailey, M.A., Wildman, S.S.P., Tam, F.W.T. & Unwin, R.J. 2013. Extracellular nucleotides and renal function. In: R. Alpern, M. Caplan & O. Moe (eds) Seldin and Giebisch's The Kidney. 5th edn, pp. 511-537. Academic Press/Elsevier, London.
71. Sipos, A., Vargas, S.L., Toma, I., Hanner, F., Willecke, K. & Peti-Peterdi, J. 2009. Connexin 30 deficiencey impairs renal tubular ATP release and pressure natriuresis. J Am Soc Nephrol 20, 1724-1732.
72. Stockand, J.D. 2010. Vasopressin regulation of renal sodium excretion. Kidney Int 78, 849-856.
73. Sugawara, M., Hashimot, K. & Ota, Z. 1988. Involvement of prostaglandin E2, cAMP, and vasopressin in lithium-induced polyuria. Am J Physiol Regul Integr Comp Physiol 254, R863-R869.
74. 2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol 289, F585-F591.
75. 2 receptor-mediated PGE2 release by IMCD. Am J Physiol Renal Physiol 289, F768-F776.
76. Sundin, J., Fear, N.T., Iversen, A., Rona, R.J. & Wessley, S. 2010. PTSD after deployment to Iraq: conflicting rates, conflicting claims. Psychol Med 40, 367-382.
77. Svenningsen, P., Burford, J.L. & Peti-Peterdi, J. 2013. ATP releasing connexin 30 hemichannels mediate flow-induced calcium signaling in the collecting duct. Front Physiol 4, 292.
78. Vallon, V. & Rieg, T. 2011. Regulation of renal NaCl and water transport by the ATP/UTP/P2Y2 receptor system. Am J Physiol Renal Physiol 301, F463-F475.
79. Wada, A., Yokoo, H., Yanagita, T. & Kobayashi, H. 2005. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci 99, 307-321.
80. Walker, R.J., Leader, J.P., Bedford, J.J., Gobe, G.C., Davis, G., Vos, F.E., Dejong, S. & Schollum, J.B. 2013. Chronic interstitial fibrosis in the rat kidney induced by long-term (6-mo) exposure to lithium. Am J Physiol Renal Physiol 304, F300-F307.
81. Weinstock, R.S. & Moses, A.M. 1990. Desmopressin and indomethacin therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate. South Med J 83, 1475-1477.
82. 2 receptor-stimulated release of prostaglandin E2 by rat inner medullary collecting duct preparations. Am J Physiol Renal Physiol 285, F711-F721.
83. 2 receptor antagonists. Bioorg Med Chem Lett 18, 223-227.
84. Wildman, S.S., Marks, J., Turner, C.M., Yew-Booth, L., Peppiat-Wildman, C.M., King, B.F., Shirley, D.G., Wang, W. & Unwin, R.J. 2008. Sodium-dependent regulation of renal amiloride-sensitive currents by apical P2 receptors. J Am Soc Nephrol 19, 731-742.
85. Wilson, J.L.L., Miranda, C.A. & Knepper, M.A. 2013. Vasopressin and the regulation of aquaporin-2. Clin Exp Nephrol 17, 751-764.
86. Young, W. 2009. Review of lithium effects on brain and blood. Cell Transplant 18, 951-975.
87. 2 receptor gene knockout mice. Am J Physiol Renal Physiol 295, F1715-F1724.
88. Zhang, Y., Nelson, R.D., Carlson, N.G., Kamerath, C.D., Kohan, D.E. & Kishore, B.K. 2009. Potential role of purinergic signaling in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 296, F1194-F1201.
89. 2 receptor in diuresis of potobstructive uropathy in rats. Am J Physiol Renal Physiol 298, F634-F642.
90. 2 receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE2 signaling. Am J Physiol Renal Physiol 302, F70-F77.
91. 2 receptor knockout mice. Am J Physiol Renal Physiol 305, F407-F416.
92. 12 receptor in complex with an antithrombotic drug. Nature 509, 115-118.
93. 12 receptor localizes in rat renal collecting duct, and its blockade augments AVP action and alleviates lithium-induced NDI. J Am Soc Nephrol [Epub ahead of print].